1
项与 shRNA-modified CD34 cell therapy(Kanglin Biotech (Hangzhou) Co Ltd) 相关的临床试验A Pilot Study to Evaluate Efficacy and Safety of Multiplexed shRNA-modified CD34+ Cells in HIV-infected Patients.
The purpose of the study is to evaluate the efficacy and safety of autologous CD34+ cells that stably express multiplexed shRNA to treat HIV infection.
100 项与 shRNA-modified CD34 cell therapy(Kanglin Biotech (Hangzhou) Co Ltd) 相关的临床结果
100 项与 shRNA-modified CD34 cell therapy(Kanglin Biotech (Hangzhou) Co Ltd) 相关的转化医学
100 项与 shRNA-modified CD34 cell therapy(Kanglin Biotech (Hangzhou) Co Ltd) 相关的专利(医药)
100 项与 shRNA-modified CD34 cell therapy(Kanglin Biotech (Hangzhou) Co Ltd) 相关的药物交易